Merck Announces Third-Quarter 2017 Dividend
Dateline City:
KENILWORTH, N.J.KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada,
today announced that the Board of Directors has declared a quarterly
dividend of $0.47 per share of the company ’s common stock for the third
quarter of 2017. Payment will be made on July 10, 2017 to shareholders
of record at the close of business on June 15, 2017.About MerckLanguage:
EnglishContact: Media:Tracy Ogden, 908-740-1747Claire Gillespie, 267-305-0932Investor:Teri Loxam, 908-740-1986Amy Klug, 908-740-1898Ticker Slug:Ticker:MRKExchange:NY...
Source: Merck.com - Corporate News - May 23, 2017 Category: Pharmaceuticals Tags: Corporate News Financial News Latest News #Merck #MRK $MRK MSD NYSE:MRK Source Type: news
Data for KEYTRUDA ® (pembrolizumab) Across 16 Types of Cancer from Merck’s Industry-Leading Immuno-Oncology Program to Be Presented at the 2017 ASCO Annual Meeting
Dateline City:
KENILWORTH, N.J. Research with KEYTRUDA in Monotherapy and in Combination Includes Findings in Non-Small Cell Lung Cancer (NSCLC), Melanoma, Urothelial Carcinoma, Microsatellite-Instability High (MSI-H) Cancers, Gastric Cancer and Breast Cancer New Overall Survival Data to be Presented in NSCLC, Melanoma and Urothelial CarcinomaKENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada,
today announced that new and updated data from studies of KEYTRUDA®
(pembrolizumab), the company ’s anti-PD-1 therapy, will be presented at
...
Source: Merck.com - Corporate News - May 17, 2017 Category: Pharmaceuticals Tags: Oncology Newsroom Corporate News Latest News #Merck #MRK $MRK NYSE: MRK Source Type: news
Merck to Present at the Deutsche Bank 42nd Annual Health Care Conference
Dateline City:
KENILWORTH, N.J.KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada,
announced today that Roger Perlmutter, president, Merck Research
Laboratories, is scheduled to present at the Deutsche Bank 42nd Annual
Health Care Conference in Boston on May 4, 2017 at 8:40 a.m. EDT.
Investors, analysts, members of the media and the general public are
invited to listen to a live audio webcast of the presentation at http://investors.merck.com/events-and-presentations/default.aspx.About MerckLanguage:
EnglishContact: Media:Claire ...
Source: Merck.com - Corporate News - May 3, 2017 Category: Pharmaceuticals Tags: Corporate News Financial News Latest News #Merck #MRK $MRK MSD NYSE:MRK Source Type: news
Merck Announces First-Quarter 2017 Financial Results
Dateline City:
KENILWORTH, N.J. First-Quarter 2017 Worldwide Sales Were $9.4 Billion, an Increase of 1 Percent, Including a 2 Percent Negative Impact from Foreign Exchange First-Quarter 2017 GAAP EPS Was $0.56; First-Quarter Non-GAAP EPS Was $0.88 Company Narrows and Raises 2017 Full-Year Revenue Range to be Between $39.1 Billion and $40.3 Billion, Including an Approximately 1.5 Percent Negative Impact from Foreign Exchange Company Narrows and Raises 2017 Full-Year GAAP EPS Range to be Between $2.51 and $2.63; Narrows and Raises 2017 Full-Year Non-GAAP EPS Range to be Betwe...
Source: Merck.com - Corporate News - May 2, 2017 Category: Pharmaceuticals Tags: Corporate News Financial News Latest News #Merck #MRK $MRK earnings MSD NYSE:MRK Source Type: news
America ’s Diabetes Challenge Unveils Common Challenges Affecting the Type 2 Diabetes Community
Dateline City:
KENILWORTH, N.J.Merck, the American Diabetes Association and Celebrity Voices Offer Tips to Help People Tackle Their Obstacles Head OnKENILWORTH, N.J. – Merck (NYSE: MRK), known as MSD outside the United States and Canada, and the American Diabetes Association today revealed common challenges affecting the millions of Americans living with type 2 diabetes as part of the programAmerica ’s Diabetes Challenge: Get to Your Goals. Last year, award-winning artist Tim McGraw, renowned actress S. Epatha Merkerson and Chef Leticia Moreinos Schwartz called on patients and their loved ones to share their ...
Source: Merck.com - Corporate News - April 25, 2017 Category: Pharmaceuticals Tags: Corporate News Latest News Source Type: news
Merck Donates $300,000 to Support Neglected Tropical Disease Elimination Efforts in Africa
Dateline City:
KENILWORTH, N.J.KENILWORTH, N.J.--(BUSINESS WIRE)--Merck, known as MSD outside the United States and Canada, announced
today a $300,000 cash donation to support non-governmental organization
(NGO) partners working to eliminate river blindness (onchocerciasis) and
lymphatic filariasis (LF) in Africa.Language:
EnglishContact: Merck:Claire Gillespie, 267-305-0932Jeanine Clemente, 908-740-6268orMDP:Joni Lawrence, 404-687-5610Yao Sodahlon, 404-371-1460Ticker Slug:Ticker:MRKExchange:NYSE
@Merckread more (Source: Merck.com - Corporate News)
Source: Merck.com - Corporate News - April 20, 2017 Category: Pharmaceuticals Tags: Corporate News Corporate Responsibility News Latest News #Merck #MRK $MRK MSD NYSE:MRK Source Type: news
Togo Becomes First Country in Africa to Validate the Elimination of Lymphatic Filariasis as a Public Health Problem
Dateline City:
LOME, TOGOLOME, TOGO -- GSK, Merck (known as MSD outside the United States and Canada), and the MECTIZAN® Donation Program (MDP) congratulate President Faure Gnassingb é, the government and the people of Togo for becoming the first country in Africa recognized by the World Health Organization to have eliminated lymphatic filariasis (LF) as a public health problem.Language:
Englishread more (Source: Merck.com - Corporate News)
Source: Merck.com - Corporate News - April 18, 2017 Category: Pharmaceuticals Tags: Corporate News Corporate Responsibility News Latest News Source Type: news
Dr. John H. Noseworthy Nominated to Stand for Election to Merck Board of Directors
Dateline City:
KENILWORTH, N.J.KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada,
today announced that Dr. John H. Noseworthy, president and chief
executive officer of Mayo Clinic, has been nominated to stand for
election to the company ’s board of directors. The annual election of Dr.
Noseworthy and the other directors will take place in connection with
Merck’s Annual Meeting of Shareholders on May 23, 2017. With the
proposed addition of Dr. Noseworthy, and the planned retirement of C.Language:
EnglishContact: MerckMed...
Source: Merck.com - Corporate News - April 10, 2017 Category: Pharmaceuticals Tags: Corporate News Latest News #Merck #MRK $MRK MSD NYSE:MRK Source Type: news
Merck Receives Complete Response Letter from the U.S. FDA for TECOS Study with Sitagliptin
Dateline City:
KENILWORTH, N.J.KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada,
today announced that the U.S. Food and Drug Administration (FDA) has
issued a Complete Response Letter regarding Merck ’s Supplemental New
Drug Applications for JANUVIA®(sitagliptin), JANUMET®
(sitagliptin and metformin HCl) and JANUMET XR® (sitagliptin
and metformin HCl extended-release).Language:
EnglishContact: MerckMedia:Pamela Eisele, 267-305-3558orKristen Drake, 908-236-4223orInvestors:Amy Klug, 908-740-1898Ticker Slug:Ticker:MRKExcha...
Source: Merck.com - Corporate News - April 7, 2017 Category: Pharmaceuticals Tags: Corporate News Latest News #Merck #MRK $MRK MSD NYSE:MRK Source Type: news
Merck Receives 2017 ENERGY STAR Sustained Excellence Award from U. S. Environmental Protection Agency
Dateline City:
KENILWORTH, N.J. Company Receives EPA Honor for 12th Consecutive YearKENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada,
announced today that it has received an ENERGY STAR 2017 Partner of the
Year – Sustained Excellence Award from the U.S. Environmental Protection
Agency (EPA) for its continued improvement of energy performance and
leadership in energy management in both the pharmaceutical and
industrial sectors.Language:
EnglishContact: MerckMedia:Claire Gillespie, 267-305-0932orInvestors:Amy Klug, 908-74...
Source: Merck.com - Corporate News - April 6, 2017 Category: Pharmaceuticals Tags: Corporate News Corporate Responsibility News Latest News #Merck #MRK $MRK Energy Star MSD NYSE:MRK Source Type: news
Merck to Hold First-Quarter 2017 Sales and Earnings Conference Call on May 2
Dateline City:
KENILWORTH, N.J.KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada,
will hold its first-quarter 2017 sales and earnings conference call with
institutional investors and analysts at 8:00 a.m. EDT on Tuesday, May 2.
During the call, company executives will provide an overview of Merck ’s
performance for the quarter and year.Language:
EnglishContact: MerckMedia:Claire Gillespie, 267-305-0932orInvestors:Teri Loxam, 908-740-1986Amy Klug, 908-740-1898Ticker Slug:Ticker:MRKExchange:NYSE
@Merckread more (Source...
Source: Merck.com - Corporate News - April 3, 2017 Category: Pharmaceuticals Tags: Corporate News Financial News Latest News #Merck #MRK $MRK earnings MSD NYSE:MRK Source Type: news
Incyte and Merck Provide Additional Details on Previously Announced Collaboration Investigating Epacadostat and KEYTRUDA ® (pembrolizumab)
Dateline City:
WILMINGTON, Del.& KENILWORTH, N.J.Clinical Program Now Includes Seven Registrational Trials Across Five Tumor TypesWILMINGTON, Del.& KENILWORTH, N.J.–Incyte Corporation (Nasdaq:INCY) and Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced additional details of their clinical development program investigating the combination of epacadostat, Incyte ’s investigational oral selective IDO1 enzyme inhibitor, with KEYTRUDA® (pembrolizumab), Merck ’s anti-PD-1 therapy, in patients across five tumor types: metastatic melanoma, non-small cell lung cancer (NSCLC), bladd...
Source: Merck.com - Corporate News - March 31, 2017 Category: Pharmaceuticals Tags: Oncology Newsroom Corporate News Latest News Source Type: news
Merck Animal Health Completes Acquisition of Vall ée S.A.
Dateline City:
MADISON, N.J. Broadening Our Comprehensive Portfolio of Animal Health Products for Brazilian MarketMADISON, N.J.--(BUSINESS WIRE)--Merck Animal Health (known as MSD Animal Health outside the United
States and Canada) today announced it has successfully acquired a
controlling interest in Vall ée S.A., a leading privately-held producer
of animal health products in Brazil.Language:
EnglishContact: For MerckMedia:Noreen Verbrugge, 973-937-5450orPamela Eisele, 267-305-3558orInvestors:Michael DeCarbo, 908-740-1807Ticker Slug:Ticker:MRKExchange:NYSE
@MerckAH...
Source: Merck.com - Corporate News - March 22, 2017 Category: Pharmaceuticals Tags: Corporate News Animal Health Latest News #Merck #MRK $MRK Merck Animal Health MSD NYSE:MRK Vall ée S.A. Source Type: news
FDA Approves Merck ’s KEYTRUDA® (pembrolizumab) for Adult and Pediatric Patients with Classical Hodgkin Lymphoma (cHL) Refractory to Treatment, or Who Have Relapsed After Three or More Prior Lines of Therapy
Dateline City:
KENILWORTH, N.J. Only Anti-PD-1 Therapy Approved for the Treatment of Patients with Difficult-to-Treat cHL Regardless of Prior Stem Cell Transplantation or Use of Brentuximab VedotinKENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada,
today announced that the U.S. Food and Drug Administration (FDA) has
approved KEYTRUDA®(pembrolizumab), the company ’s anti-PD-1
(programmed death receptor-1) therapy, for the treatment of adult and
pediatric patients with refractory classical Hodgkin lymphoma (cHL), or
who have relapse...
Source: Merck.com - Corporate News - March 14, 2017 Category: Pharmaceuticals Tags: Corporate News Latest News #Merck #MRK $MRK NYSE:MRK Source Type: news
Merck Provides Update on Supplemental Biologics License Application (sBLA) for KEYTRUDA ® (pembrolizumab) in Previously Treated Advanced Microsatellite Instability-High Cancer
Dateline City:
KENILWORTH, N.J.KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada,
today announced that the U.S. Food and Drug Administration (FDA) has
extended the action date for the supplemental Biologics License
Application (sBLA) for KEYTRUDA®(pembrolizumab), the
company ’s anti-PD-1 therapy, for previously treated patients with
advanced microsatellite instability-high (MSI-H) cancer. The company
recently submitted additional data and analyses to the FDA related to
the pending application.Language:
EnglishContact: ...
Source: Merck.com - Corporate News - March 14, 2017 Category: Pharmaceuticals Tags: Corporate News Latest News #Merck #MRK $MRK NYSE: MRK Source Type: news
